Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiological framework was timely and necessary. An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary. This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease / M.F. Bastide, W.G. Meissner, B. Picconi, S. Fasano, P. Fernagut, M. Feyder, V. Francardo, C. Alcacer, Y. Ding, R. Brambilla, G. Fisone, A. Jon Stoessl, M. Bourdenx, M. Engeln, S. Navailles, P. De Deurwaerdère, W.K.D. Ko, N. Simola, M. Morelli, L. Groc, M. Rodriguez, E.V. Gurevich, M. Quik, M. Morari, M. Mellone, F. Gardoni, E. Tronci, D. Guehl, F. Tison, A.R. Crossman, U.J. Kang, K. Steece-Collier, S. Fox, M. Carta, M.A. Cenci, E. Bézard. - In: PROGRESS IN NEUROBIOLOGY. - ISSN 0301-0082. - 132(2015), pp. 96-168.

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

M. Mellone;F. Gardoni;
2015

Abstract

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately experienced by the vast majority of patients. In addition, psychiatric conditions often manifested as compulsive behaviours, are emerging as a serious problem in the management of L-dopa therapy. The present review attempts to provide an overview of our current understanding of dyskinesia and other L-dopa-induced dysfunctions, a field that dramatically evolved in the past twenty years. In view of the extensive literature on LID, there appeared a critical need to re-frame the concepts, to highlight the most suitable models, to review the central nervous system (CNS) circuitry that may be involved, and to propose a pathophysiological framework was timely and necessary. An updated review to clarify our understanding of LID and other L-dopa-related side effects was therefore timely and necessary. This review should help in the development of novel therapeutic strategies aimed at preventing the generation of dyskinetic symptoms.
Animal models; D1 receptor; Dopamine; Dyskinesia; L-dopa; Parkinson's disease; Neuroscience (all)
Settore BIO/14 - Farmacologia
2015
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0301008215000763-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 4.54 MB
Formato Adobe PDF
4.54 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/320188
Citazioni
  • ???jsp.display-item.citation.pmc??? 121
  • Scopus 340
  • ???jsp.display-item.citation.isi??? 330
social impact